TRIM59 DIRECTED DIAGNOSTICS FOR NEOPLASTIC DISEASE

• US 20090233295A1
• Filed: 01/29/2009
• Published: 09/17/2009
• Est. Priority Date: 01/29/2008
• Status: Abandoned Application

• Current Assignee: Aurelium BioPharma, Inc.
• Original Assignee: Aurelium BioPharma, Inc.
• Inventors: GEORGES, ELIAS, BONNEAU, ANNE-MARIE
• Application Number:
  US12/361,784
• Publication Number:
  US 20090233295A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 33/57484 involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Abstract

Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of TRIM59 in the test cell sample or fluid sample as compared to the level of expression of TRIM59 in a control cell sample or fluid sample isolated from a normal subject.

Claims

1. A method for detecting a neoplasm comprising:

a) obtaining a potentially neoplastic test sample and a corresponding non-neoplastic control sample;

b) detecting a level of TRIM59 expression in the test sample and in the control sample; and

c) comparing the level of TRIM59 expression in the test sample to the level of TRIM59 expression in the control sample,

the test sample being neoplastic if the level of TRIM59 expression in the test sample is detectably greater than the level of TRIM59 expression in the control sample.

2. The method of claim 1, wherein the neoplastic test sample and the control samples are cell samples of the same lineage.

3. The method of claim 2, wherein detecting the level of expression of TRIM59 comprises isolating a cytoplasmic fraction from the test cell sample and from the control cell sample, and then separately detecting the level of expression of TRIM59 in these cytoplasmic fractions.

4. The method of claim 1, wherein the level of expression of TRIM59 protein is detected by contacting the test sample and the control sample with a TRIM59-specific protein binding agent selected from the group consisting of an anti-TRIM59 antibody, TRIM59-binding portions of an antibody, TRIM59-specific ligands, TRIM59-specific aptamers, and TRIM59 inhibitors.

5. The method of claim 4, wherein the TRIM59-specific protein binding agent is immobilized on a solid support.

6. The method of claim 1, wherein TRIM59 expression is detected by detecting the level of expression of TRIM59 RNA by contacting the test sample and the control sample with a TRIM59 RNA-specific nucleic acid binding agent and determining how much of the nucleic acid binding agent is hybridized to TRIM59 RNA n the test sample and in the control sample.

7. The method of claim 6, wherein the nucleic acid binding agent is immobilized on a solid support.

8. The method of claim 1, wherein the level of expression of TRIM59 in the test sample is at least 1.5, at least 21, at least 4, at least 8, at least 10, or at least 20 times greater than the level of expression of TRIM59 in the control sample.

9. The method of claim 1, wherein the test sample is isolated from a patient suffering from ovarian cancer.

10. The method of claim 1, wherein the test sample is isolated from a patient suffering from breast cancer.

11. The method of claim 1, wherein the test sample is isolated from a patient suffering from colon cancer.

12. The method of claim 1, wherein the test sample is isolated from a patient suffering from lung cancer.

13. The method of claim 1, wherein the test sample is isolated from a patient suffering from melanoma.

14. The method of claim 1, wherein the test sample is isolated from a patient suffering from sarcoma.

15. The method of claim 1, wherein the test sample is isolated from a patient suffering from leukemia.

16. The method of claim 1, wherein the test sample and the control samples are fluid samples.

17. The method of claim 16, wherein the level of TRIM59 protein expression is determined by measuring the level of anti-TRIM59 antibody in the test fluid sample and in the control fluid sample.

18. The method of claim 17, wherein the test and control fluid samples are serum samples.

19. The method of claim 17, wherein the level of expression of anti-TRIM59 antibody is detected with an anti-TRIM59 antibody-specific antibody, or anti-TRIM59 antibody-specific antibody fragment thereof.

20. A method for detecting a neoplasm comprising:

a) obtaining a potentially neoplastic test sample and a non-neoplastic control sample;

b) detecting a level of TRIM59 expression in the test sample and in the control sample;

c) detecting a level of expression of at least one of TTK, SLC7A5, UHRF1, and/or KIF20A; and

d) comparing the level of TRIM59 expression and the level of expression of at least one of SLC7A5, UHRF1, TTK, and/or KIF20A in the test sample to the level of TRIM59 expression and the level of expression of the at least one of SLC7A5, UHRF1, TTK, and/or KIF20A in the control sample,

the test sample being neoplastic if the levels of expression of TRIM59 and the at least one of SLC7A5, UHRF1, TTK, and/or KIF20 in the test sample are detectably greater than the levels of expression of TRIM59 and the at least one of SLC7A5, UHRF1, TTK, and/or KIF20A in the control sample.

21. The method of claim 20, wherein detecting step (c) comprises detecting the expression of at least SLC7A5, and comparing step (d) comprises comparing the levels of TRIM59 expression and at least SLC7A5 expression in the test and control samples.

22. The method of claim 20, wherein the level of TRIM59 expression is detected by contacting the test sample and the control sample with a TRIM59-specific protein binding agent selected from the group consisting of an TRIM59-specific antibody, TRIM59-specific binding portions of an antibody, a TRIM59-specific ligand, a TRIM59-specific aptamer, and an TRIM59 inhibitor.

23. The method of claim 22, wherein the TRIM59-specific protein binding agent is immobilized on a solid support.

24. The method of claim 20, wherein the level of expression of TRIM59 in the test and control samples is measured by measuring the level of TRIM59 RNA and the level of at least one of SLC7A5 RNA, UHRF1 RNA, TTK RNA, and/or KIF20A RNA in the test and control samples.

25. The method of claim 24, wherein the level of expression of TRIM59 RNA and the level of expression of at least one of SLC7A5 RNA, UHRF1 RNA, TTK RNA, and/or KIF20A RNA are detected by contacting the test sample and the control sample with an TRIM59-specific nucleic acid binding agent and with at least one of a SLC7A5-specific nucleic acid binding agent, a UHRF1-specific nucleic binding agent, a TTK-specific nucleic acid binding agent, and a KIF20A-specific nucleic acid binding agent.

26. The method of claim 25, wherein the level of expression of TRIM59 is measured by detecting a level of anti-TRIM59 antibody in a test fluid sample and in a control fluid sample.

27. The method of claim 20, wherein the levels of expression of TRIM59, SLC7A5, UHRF1, TTK, and/or KIF20 in the test sample are at least 1.5 times greater than the level of expression of TRIM59, SLC7A5, UHRF1, TTK, and/or KIF20 in the control sample.

28. The method of claim 20, wherein the test and control samples are cell samples.

29. The method of claim 28, wherein detecting the level of expression of TRIM59 and the level of expression of at least one of SLC7A5, UHRF1, TTK and/or KIF20A comprises isolating a cytoplasmic fraction from the test cell sample and from the control cell sample, and then detecting the levels of expression of TRIM59 and at least one of SLC7A5, UHRF1, TTK and/or KIF20A in each of these cytoplasmic fractions.

30. The method of claim 20, wherein the test and control samples are fluid samples.

31. The method of claim 30, wherein the level of expression of TRIM59 is measured by detecting a level of anti-TRIM59 antibody in a test fluid sample and in a control fluid sample.

32. The method of claim 20, wherein the test sample is isolated from a tissue of a patient suffering from ovarian cancer, breast cancer, lung cancer, sarcoma, melanoma, or leukemia.

33. A kit for diagnosing or detecting neoplasia, comprising:

a) a first probe specific for the detection of TRIM59; and

b) a second probe specific for the detection of a neoplasia marker selected from the group consisting of SLC7A5, UHRF1, TTK, KIF20A, and combinations thereof.